The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma-Reference-Cited by-同舟云学术

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma

Published:2018-07-25 Issue:14 Volume:3 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Giricz Orsi^ORCID,Mo Yongkai,Dahlman Kimberly B.,Cotto-Rios Xiomaris M.,Vardabasso Chiara,Nguyen Hoa,Matusow Bernice,Bartenstein Matthias^ORCID,Polishchuk Veronika,Johnson Douglas B.,Bhagat Tushar D.,Shellooe Rafe,Burton Elizabeth,Tsai James,Zhang Chao,Habets Gaston,Greally John M.,Yu Yiting,Kenny Paraic A.,Fields Gregg B.,Pradhan Kith,Stanley E. Richard,Bernstein Emily,Bollag Gideon,Gavathiotis Evripidis^ORCID,West Brian L.,Sosman Jeffrey A.,Verma Amit K.

Funder

Pershing Square Sohn Cancer Research Alliance and Department of Defense

NCI

NIH

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/120422/files/pdf

Reference68 articles.

1. Howlader N, et al. SEER Cancer Statistics Review, (CSR) 1975-2015. National Cancer Institute. https://seer.cancer.gov/csr/1975_2015/ Published April 16, 2018. Accessed June 27, 2018

2. Genomic Classification of Cutaneous Melanoma

3. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

4. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

5. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067);Wolchok;J Clin Oncol,2016

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of CSF1R 550th-tryptophan in kusunokinin and CSF1R inhibitor binding and ligand-induced structural effect;Scientific Reports;2024-05-31

2. The molecular determinants of microglial developmental dynamics;Nature Reviews Neuroscience;2024-04-24

3. Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma;Expert Review of Clinical Immunology;2024-03-27

4. RUNX transcription factors: biological functions and implications in cancer;Clinical and Experimental Medicine;2024-03-02

5. CSF-1R in Cancer: More than a Myeloid Cell Receptor;Cancers;2024-01-09